These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27648317)

  • 1. Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma.
    Irlé C; Weintraub J
    Case Rep Hematol; 2016; 2016():8175957. PubMed ID: 27648317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Barbarotta L; Hurley K
    J Adv Pract Oncol; 2015; 6(1):22-36. PubMed ID: 26413372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving gastrointestinal quality of life: romidepsin to tucidinostat in a case of angioimmunoblastic T cell lymphoma.
    Isoda A; Terasaki Y; Kanaya S; Saito A
    BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38199657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
    Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
    Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
    J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
    Brunvand MW; Carson J
    Hematol Oncol; 2018 Feb; 36(1):340-343. PubMed ID: 28560733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
    Shustov A; Coiffier B; Horwitz S; Sokol L; Pro B; Wolfson J; Balser B; Eisch R; Popplewell L; Prince HM; Allen SL; Piekarz R; Bates S
    Leuk Lymphoma; 2017 Oct; 58(10):2335-2341. PubMed ID: 28264616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.
    Foss F; Coiffier B; Horwitz S; Pro B; Prince HM; Sokol L; Greenwood M; Lerner A; Caballero D; Baran E; Kim E; Nichols J; Balser B; Wolfson J; Whittaker S
    Biomark Res; 2014; 2():16. PubMed ID: 25279222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romidepsin for the treatment of T-cell lymphomas.
    McGraw AL
    Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
    Lunning MA; Horwitz S
    Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma.
    Moskowitz AJ
    J Oncol Pract; 2019 Mar; 15(3):137-143. PubMed ID: 30861367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.
    Han B; Lim S; Yim J; Song YK; Koh J; Kim S; Lee C; Kim YA; Jeon YK
    J Pathol Transl Med; 2024 Mar; 58(2):59-71. PubMed ID: 38247153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral T-cell lymphoma with follicular T-cell markers.
    Rodríguez-Pinilla SM; Atienza L; Murillo C; Pérez-Rodríguez A; Montes-Moreno S; Roncador G; Pérez-Seoane C; Domínguez P; Camacho FI; Piris MA
    Am J Surg Pathol; 2008 Dec; 32(12):1787-99. PubMed ID: 18779728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
    J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.